BPN711: Point-of-Care System for Quantitative Measurements of Blood Analytes Using Graphene-Based Sensors


Serum glucose, cholesterol, triglyceride and HbA1C monitoring are all valuable tools in the health management of the aging population, especially given the increase in diabetes and cardiovascular diseases. Even for glucose monitoring, the challenges obtaining sufficiently accurate and reliable measurements are so significant that the FDA is contemplating more stringent standards. Guido Freckmann, et al., J. Diabetes Sci. Tech. 6, 1060-1075, 2012, have compared 43 blood glucose self- monitoring systems. Out of this, 34 systems were completely assessed and 27 (79.4%) systems fulfilled the minimal accuracy requirements and only 18 (52.9%) of 34 systems fulfilled the requirements of the proposed tighter criteria in the current standards draft. None of them meet the even more stringent requirement of ISO 2012 and FDA. Because inaccurate systems bear the risk of false therapeutic decisions and rising health care costs, there is an urgent need for significantly enhanced BG monitoring systems for PC applications. POC tests for other biomedically important analytes are generally even less accurate. The overall goal of the proposed research is to develop new sensor platforms that will provide increased sensitivity and accuracy in point-of-care situations. This is a joint project with Harvard Medical School and Vanderbilt University.

Project end date: 08/17/17

Publication date: 
August 15, 2017
Publication type: 
BSAC Project Materials (Final/Archive)
PREPUBLICATION DATA - ©University of California 2017

*Only registered BSAC Industrial Members may view project materials & publications. Click here to request member-only access.